For the quarter ending 2025-12-31.
| Income Statement | 2025-12-31 | 2025-09-30 | 2025-06-30 | |
|---|---|---|---|---|
| General and administrative | 2,126 | 316* | 4,500 | |
| Research and development | 4,656 | 7,715* | 9,959 | |
| Total operating expenses | 6,782 | 8,031 | 14,459 | |
| Operating loss | -6,782 | -8,031* | -14,459 | |
| Grant income | - | -38* | 25 | |
| Research and development incentive income | 33 | 267* | 127 | |
| Interest income, net | 1,079 | 1,453* | 1,075 | |
| Foreign exchange gain (loss) | 7 | -299* | -11 | |
| Total other income, net | 1,119 | 1,383* | 1,216 | |
| Net loss before provision for income taxes | -5,663 | - | - | |
| Income tax expense, current | 18 | - | - | |
| Net loss and comprehensive loss | -5,681 | -6,648 | -13,243 | |
| Basic EPS | -0.06 | -0.078 | -0.16 | |
| Diluted EPS | -0.06 | -0.078 | -0.16 | |
| Basic Average Shares | 89,029,458 | 85,198,307 | 85,380,587 | |
| Diluted Average Shares | 89,029,458 | 85,198,307 | 85,380,587 | |
ANAVEX LIFE SCIENCES CORP. (AVXL)
ANAVEX LIFE SCIENCES CORP. (AVXL)